


Nationwide Newsworthy Drugs

Jimmy Leonard, PharmD, DABAT Managing Director, Washington Poison Center

Objective

Describe recent newsworthy drugs and treatments





NOTES: Data are age adjusted by the direct method to U.S. Census 2000 estimates using age groups 20–39, 40–59, and 60–74. Overweight is body mass index (BMI) of 25.0–29.9 kg/m². Obesity is BMI at or above 30.0 kg/m². Severe obesity is BMI at or above 40.0 kg/m². Pregnant women are excluded from the analysis. SOURCES: National Center for Health Statistics, National Health Examination Survey and National Health and Nutrition Examination Surveys.



Obesity treatment

Most drugs have shown limited success

- Many drugs have been removed from the market due to SEVERE adverse events
 - Amphetamines
 - Fen-phen
 - Sibutramine
 - Rimonabant
 - Lorcaserin



GLP1-RA

- Glucagon-like peptide-1 receptor agonists (GLP1)
 - Newer medication for treatment of diabetes and obesity
 - GLP-1 secreted by intestinal tract
 - Potentiates insulin and inhibits glucagon
 - Enhance satiety, decrease appetite, increase energy consumption
 - Decrease gastrointestinal motility
- Dosing ranges from twice daily to weekly
- Weight reduction up to 20% reported
- Expected adverse effects



Semaglutide and tirzepatide

- Weekly administration
- 12.4% weight loss
- NNT for % weight loss
 - 5%: ~2
 - 10%: ~2
 - 15%: ~2

- Weekly administration
- 12-18% weight loss
- NNT for % weight loss
 - 5%: ~2
 - 20%: ~2



Shortages

- Shortages reported for semaglutide products
 - Initial shortage in 12/2021 (brand name for weight loss)
- Shortages reported for tirzepatide 7/2023
- Widespread, significantly driven by news coverage



Compounding

- Federal Food, Drug and Cosmetic Act
 - Sections 503A, 503B
- FDA-approved product does not meet the clinical needs of the patient
 - Allergy, formulation, dose, shortage



Compounding

- 503A
 - Local pharmacy
 - Compounds to fill prescription
 - Limited supply
 - Local regulation


- 503B
 - Outsourcing facility
 - Compound to sell to pharmacies
 - Large batches
 - Regulated by FDA



Weight Loss Programs, Backed by Science, Driven by Outcome

- (Affordable Weight Loss for Everyone
- **♥** Includes Doctor & Medication
- HIPAA Compliant
- FDA Licensed Pharmacy

GET STARTED



AS SEEN ON







Men's Health Forbes Medscape



Semaglutide Weight Loss Program

Price

\$295

**** 329 Reviews

Embark on a transformative weight loss journey with our Semaglutide injection, expertly guided by board-certified physicians. Our program integrates monthly, personalized compounded Semaglutide prescriptions with regular virtual check-ins, and unlimited messaging with providers. Join a thriving community of thousands achieving healthier lifestyles with semaglutide online.

Same active ingredient as Ozempic® and Wegovy®

Order Now

- Lose up to 15% of body weight*
- Ships free in 2-3 days, if prescribed
- Third-party tested for quality
- In stock, ready to ship





Tweet




Pin it



Compounded GLP1-RA

- Instructions:
 - "INJ SUBQ 0.05ML WEEKY WK1-4, 0.1ML WK5-8, 0.2ML WK9-12, 0.34ML WK13-16, THEN 0.48ML WKLY"
 - Qty: 2.5 mL
- 100-unit insulin needle
- 10-fold dosing errors common (related to units)
- Rapid escalation by days





Other issues

- "Natural Ozempic" TikTok trend
 - Rice-zempic combination of uncooked rice, hot water, and lime juice
 - Risk of bacterial food poisoning (bacillus cereus)
- Counterfeits
 - Different drugs in pens (insulin)
 - May cause severe adverse effects



Public health implications

- Potential long-term savings at short-term cost
- Risks from compounded agents
- Rare side effects scale




Tianeptine

- Antidepressant developed in the 1960s
- European, Asian, and Latin American countries
- Not approved in the United States
 - Unpublished phase 1 trial performed in 2009
- Poison center cases on the rise
- Scheduled in some states









Tianeptine

- Opioid activity
- Only antidepressant where doctor-shopping identified in a French study
- Therapeutic use: 25 50 mg/day
- Several gram doses reported in misuse and abuse
- Typical course:
 - Increasing dose over time
 - Tolerance
 - Severe withdrawal
 - Opioid-like symptoms



Clinical effects

Desirable


- Euphoria
- Contentedness
- Analgesia
- Nodding off
- Decrease anxiety
- Feeling OK
 - Feel like true self

Undesirable

- Agitation
- Tachycardia
- Hypertension
- Confusion
- Severe lethargy
- Withdrawal (opioid-like)



Reddit posts





Tianeptine contamination

- June November 2023
- 20 severe tianeptine poisoning cases reported to NJ poison center
- 14/17 patient reported using Neptune's Fix
- Seizure (8), cardiac arrest (1), ventricular arrhythmia (4)
- 7/17 intubated
- Six samples evaluated by laboratory:
 - All contained kavain
 - 2 contained synthetic cannabinoids



Public health implications

- Withdrawal management complicated
- Issues with contamination and misbranding
- Acute = opioid
- Long-term = antidepressant



Marijuana Analogues

- Classic delta-9 THC
 - Location of a double-bond
- Analogues
 - Delta-8, delta-10, HHC, THC-O, THC-B, THC-H, THCP
 - May be naturally occurring
 - Often synthesized from CBD
- Dose response may be variable





Marijuana analogues

- Similar intoxicating effects
- Known contamination with delta-9 THC
 - Issue in other states

 Use more common in Southern states compared with Western





Legality?

- 2018 Farm bill legalized CBD
 - Products with < 0.3% THC

- Analogues in trace amounts in hemp (< 0.1%)
 - CBD converted to delta9, then delta8
- Specifically banned in Washington
 - Fewer manufacturing controls
 - "small business impact"



Marijuana scheduling

- Department of Health and Human Services (DHHS)
 - Proposed schedule 3
- Drug Enforcement Administration (DEA)
 - Similar proposal consistent with DHHS
- Implications for use: none
- Implications for research: massive



Schedule III substances

- May cause physical dependence
- Moderate to low potential for dependence
 - Anabolic steroids
 - Ketamine
 - Testosterone
 - Acetaminophen with codeine (<90 mg/tablet)



Marijuana scheduling

- Still unapproved as a drug
 - Federally not an approval or deregulation
- More readily available for research

 Loosened regulation = more adult use = more pediatric cases



Psilocybin

- Hallucinogenic component of mushrooms
- Hallucinogenics used in the 1960s
 - Alcoholism and LSD
 - Schizophrenia
 - Depression



Psilocybin

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Authors: Guy M. Goodwin, F.Med.Sci., Scott T. Aaronson, M.D., Oscar Alvarez, M.R.C.Psych., Peter C. Arden, M.P.H., Annie Baker, R.G.N., James C. Bennett, M.Sc., Catherine Bird, M.Sc., 466, and Ekaterina Malievskaia, M.D. Author Info & Affiliations

Published November 2, 2022 | N Engl J Med 2022;387:1637-1648 | DOI: 10.1056/NEJMoa2206443

Single-Dose Psilocybin Treatment for Major Depressive Disorder

A Randomized Clinical Trial

Charles L. Raison, MD¹; Gerard Sanacora, MD, PhD²; Joshua Woolley, MD, PhD^{3,4}; et al

» Author Affiliations | Article Information

JAMA. 2023;330(9):843-853. doi:10.1001/jama.2023.14530



Psilocybin

- Thought to reset the some of the brain
- These were:
 - Controlled trials
 - Fixed and known dose of psilocybin
 - Physician or PhD psychologist facilitators
- Not:
 - A random trip
 - An unknown amount of psilocybin from a mushroom
 - Your friend who is smoking marijuana



Public health implications


- Still considered Schedule I
- May see uptick in use, especially if approved by FDA
- Efforts needed to ensure appropriate use

 FDA recently rejected MDMA for PTSD for a multitude of reasons



Mushroom edibles

- Marketed starting ~2022
 - Initially psilocybin
 - Limited marketing regions available
 - Muscimol
- Hallucinogenic amanita muscaria
 - Sedation
 - Euphoria
 - Drowsiness





Diamond Shruumz

- Index cases: Late April or May 2024
- Patients with severe illness (seizures, coma, serotonin syndrome)
 - Required intensive care unit treatment
- As of 8/2/24
 - 113 cases; 42 hospitalizations; 2 potentially associated deaths
 - 3 cases in Washington



DEA No. RA0571996 FL License # CMTL-0003 CLIA No. 10D1094068

Certificate of Analysis

Client Information:

Diamond Shruumz

2413 S Broadway

Santa Ana, California 92707

Order # SPA230510-060001 Order Date: 2023-05-10 Sample # AAEL445

Statement of Amendment: Updated Pote



Batch # 000

Batch Date: 2023-04-24 Extracted From: N/A

Sampling Date: 2023-05-11 Lab Batch Date: 2023-05-11

Orig. Completion Date: 2023-05-17

Initial Gross Weight: 62.823 g Net Weight: 53.523 g Number of Units: 1

Net Weight per Unit: 3568.200 mg Sampling Method: MSP 7.3.1

Psilocybin

Tested

Psilocin Tested







Not Detected

Misbranded product

Flavor	Muscimol	Psilocybin or derivative	Pregabalin (Lyrica)	Kava kava
Birthday cake	0/4	3/4	0/4	2/4
Cinnamon	1/3	2/3	0/3	2/3
Cookie butter	2/3	1/3	1/3	3/3
Cookies N Cream	1/3	1/3	1/3	3/3
Dark Chocolate	0/3	1/3	1/3	3/3
Fruity Cereal	2/3	1/3	0/3	2/3

Additionally: 4-acetoxy-N,N-dimethytryptamine



FDA regulation

 Although the FDA does not have premarket approval of food products, it has the authority to approve certain ingredients before they are used in food or intended to contact food. Those include food additives (substances added intentionally to food, as well as substances that migrate to food from food contact products such as food packaging), and color additives.




Public health implications

- Small, but widespread epidemic
- Not the first contamination/misbranding issue
 - Tianeptine
 - CBD in Utah
 - E-VALI



Opioid overdoses





Management of opioid overdose

- Sternal rub
- Call 911
- Clear the mouth and open the airway (on back and chin lifted)
- Give opioid antagonist (naloxone)
- Ventilation



Nalmefene

- Longer acting medication compared with naloxone
- Recent intranasal and autoinjector approval
- Reported as "fentanyl fighter"



Intranasal opioid antagonists

Nalmefene

- Approved in 1995
- Rapid return of respiratory drive:
 - 80% at **2.5 minutes**
 - 95% at 5 minutes
- Long duration: 11.4 hours
- Prescription only
 - Standing orders 11 states
- Approved 12 years and older

Naloxone

- Approved in 1971
- Rapid return of respiratory drive:
 - 2.5 minutes to response
- Short duration: 2.1 hours
- Over the counter or prescription
 - Standing orders 50 states
- No age limit



Public health implications

- Potential new tool
- Unclear endpoints and outcomes
- May be affordability issues



Summary

- GLP1-RA meteoric rise in use and poison center calls
- Tianeptine calls on the rise, long-term treatment may be necessary
- Marijuana analogues avoiding purity and consistency regulations
- Marijuana may be rescheduled with research implications
- Psilocybin in therapeutic trials
- Mushroom gummies/edibles sickening patients
- Nalmefene is a new opioid reversal with issues

